儿童及年轻成人急性淋巴细胞白血病与淋巴母细胞淋巴瘤中的大剂量甲氨蝶呤:UKALL 2011 随机 III 期研究结果
UKALL 2011 研究纳入 2750 例 25 岁以下 ALL 或淋巴母细胞淋巴瘤患者,随机比较诱导期地塞米松 28 天与 14 天方案、大剂量甲氨蝶呤与标准 interim 维持治疗、以及维持期是否省略脉冲治疗。结果显示短程地塞米松未减少类固醇相关毒性,大剂量甲氨蝶呤未改善中枢神经系统复发率,省略脉冲对骨髓复发非劣效但无事件生存 inferior。
要点
- 短程地塞米松(14 天)与标准 28 天方案类固醇相关毒性无差异(23.8% vs 25.5%,P=.41)。
- 大剂量甲氨蝶呤与标准 interim 维持治疗的中枢神经系统复发率无差异(5 年发生率 5.3% vs 5.5%,P=.94)。
- 省略维持期脉冲对骨髓复发非劣效,但无事件生存 inferior(HR 1.34,95%CI 1.05-1.73,P=.021)。
核心结论
- 缩短诱导期地塞米松疗程未减少类固醇相关毒性,大剂量甲氨蝶呤在 UKALL 治疗骨架内未改善中枢神经系统复发率,省略脉冲对骨髓复发非劣效但无事件生存更差。
研究设计与样本
- UKALL 2011 为随机 III 期研究,2012 年 4 月至 2018 年 12 月注册 2750 例 25 岁以下 ALL 或淋巴母细胞淋巴瘤患者,其中 1902 例随机分配至 R1,1570 例至 R2。
主要发现
- 短程地塞米松组与标准地塞米松组类固醇相关毒性分别为 23.8% 与 25.5%(P=.41)。
- 标准 interim 维持治疗组与大剂量甲氨蝶呤组中枢神经系统复发风险比为 0.98(95%CI 0.65-1.49,P=.94),5 年发生率分别为 5.3% 与 5.5%。
- 无脉冲组 5 年骨髓复发率增加 1.7%(95%CI -1.5 至 4.1),风险比 1.19(95%CI 0.87-1.62,P=.27)。
- 无脉冲组无事件生存风险比 1.34(95%CI 1.05-1.73,P=.021),复发风险比 1.24(95%CI 0.96-1.62,P=.10)。
- R1 与 R2IM 各臂之间无事件生存无差异。
关键数值与推荐
- R1 比较地塞米松 28 天(6 mg/m2;标准)与 14 天(10 mg/m2;短程)。
- R2 析因随机分为四组:大剂量甲氨蝶呤联合脉冲、大剂量甲氨蝶呤无脉冲、标准 interim 维持治疗联合脉冲(标准治疗)、标准 interim 维持治疗无脉冲。
- 主要终点:R1 为类固醇相关毒性减少,R2IM 为中枢神经系统复发率,R2pulses 为骨髓复发率(仅 ALL,非劣效界值 5%)。
- 中位随访时间:R1 为 99 个月,R2 为 87 个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: UKALL 2011 randomly assigned children and young adults (younger than 25 years) with ALL or lymphoblastic lymphoma. The aims were to reduce induction toxicity (randomization 1 [R1]), CNS relapse risk (randomization 2 [R2]-interim maintenance [R2IM]), and maintenance morbidity (R2pulses). METHODS: R1 compared induction dexamethasone (dex) for 28 days (6 mg/m2; standard) with 14 days (10 mg/m2; short). R2 was a factorial randomization resulting in four arms: high-dose methotrexate (HDM) with pulses, HDM without pulses, standard interim maintenance (SIM) with pulses (standard of care), and SIM without pulses. The primary end points were reduction in steroid-related toxicity (R1), CNS relapse rate (CNSR, R2IM), and bone marrow relapse rate (BMR, R2pulses; ALL only, noninferiority margin 5%). Event-free survival (EFS) was an additional primary end point for both randomizations. RESULTS: Of 2,750 eligible patients registered between April 2012 and December 2018, 1,902 were randomly assigned to R1 and 1,570 to R2. Median follow-up is 99 (R1) and 87 months (R2). There were no differences in steroid-related toxicity between short and standard dex (23.8% v 25.5%; P = .41) and CNSR between SIM and HDM (0.98 [95% CI, 0.65 to 1.49]; P = .94; 5-year rates: SIM 5.3% and HDM 5.5%). EFS was no different between R1 and R2IM arms. BMR in the no pulses arm was noninferior (+1.7% increase at 5 years [95% CI, -1.5 to 4.1]; hazard ratio [HR], 1.19 [95% CI, 0.87 to 1.62]; P = .27). Although the EFS in the no pulses arm was inferior (1.34 [95% CI, 1.05 to 1.73]; P = .021), this was not significant for relapse (HR, 1.24 [95% CI, 0.96 to 1.62]; P = .10). CONCLUSION: Shorter duration of induction dex does not reduce steroid-related toxicity and HDM does not improve CNSR within a UKALL treatment backbone. Omission of pulses is noninferior for BMR.
引用
- Kirkwood AA, Goulden N, Moppett J, et al. High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011. J Clin Oncol. 2025. PMID: 40193822. doi:10.1200/JCO-24-01851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。